Nosatel (Dexketoprofen)

Dexketoprofen works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which blocks the synthesis of prostaglandins. Lower prostaglandin levels reduce peripheral sensitisation of pain receptors and diminish inflammatory responses, producing analgesic and anti‑inflammatory effects.

The specific dose of Nosatel is determined by the prescribing clinician based on the patient’s condition, severity of pain, and clinical judgement. Dosage may vary according to the route of administration (intramuscular or intravenous) and individual patient factors.

Safety of dexketoprofen during pregnancy and lactation has not been firmly established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To order Nosatel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Nosatel delivers dexketoprofen, which is the S‑enantiomer of ketoprofen and provides potent analgesia at lower doses compared with many traditional NSAIDs. Its rapid onset and injectable formulation make it useful for acute pain settings, while the safety profile is similar to other non‑selective NSAIDs, requiring attention to gastrointestinal, renal and cardiovascular risks.

Nosatel should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Nosatel is supplied as a sterile injectable solution and may be given either intramuscularly or intravenously by a qualified healthcare professional. The injection should be performed using aseptic technique, and the dose is administered over the time period recommended by the prescriber.

Serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for signs of bleeding, renal dysfunction, allergic reactions, and any new or worsening cardiovascular symptoms.

Nosatel should be avoided in patients with known hypersensitivity to dexketoprofen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and individuals with established high cardiovascular risk unless the benefit outweighs the risk. It is also contraindicated in patients receiving other non‑selective NSAIDs concurrently.